Trial watch: dexmedetomidine in cancer therapy
ABSTRACTDexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2327143 |
| _version_ | 1797266026510942208 |
|---|---|
| author | Killian Carnet Le Provost Oliver Kepp Guido Kroemer Lucillia Bezu |
| author_facet | Killian Carnet Le Provost Oliver Kepp Guido Kroemer Lucillia Bezu |
| author_sort | Killian Carnet Le Provost |
| collection | DOAJ |
| description | ABSTRACTDexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery, thus harboring therapeutic benefits for oncological procedures. Recently, the molecular mechanisms of DEX-mediated anticancer effects have been partially deciphered. Together with additional preclinical data, these mechanistic insights support the hypothesis that DEX-induced therapeutic benefits are mediated via the stimulation of adaptive anti-tumor immune responses. Similarly, published clinical trials including ancillary studies described an immunostimulatory role of DEX during the perioperative period of cancer surgery. The impact of DEX on long-term patient survival remains elusive. Nevertheless, DEX-mediated immunostimulation offers an interesting therapeutic option for onco-anesthesia. Our present review comprehensively summarizes data from preclinical and clinical studies as well as from ongoing trials with a distinct focus on the role of DEX in overcoming (tumor microenvironment (TME)-imposed) cancer therapy resistance. The objective of this update is to guide clinicians in their choice toward immunostimulatory onco-anesthetic agents that have the capacity to improve disease outcome. |
| first_indexed | 2024-04-25T00:54:09Z |
| format | Article |
| id | doaj.art-af61e579a22d45b2bc5db37f446947a1 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-04-25T00:54:09Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-af61e579a22d45b2bc5db37f446947a12024-03-11T12:25:15ZengTaylor & Francis GroupOncoImmunology2162-402X2024-12-0113110.1080/2162402X.2024.2327143Trial watch: dexmedetomidine in cancer therapyKillian Carnet Le Provost0Oliver Kepp1Guido Kroemer2Lucillia Bezu3Equipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, FranceEquipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, FranceEquipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, FranceEquipe Labellisée Par La Ligue Contre Le Cancer, Université de Paris, Sorbonne Université, Paris, FranceABSTRACTDexmedetomidine (DEX) is a highly selective α2-adrenoceptor agonist that is widely used in intensive and anesthetic care for its sedative and anxiolytic properties. DEX has the capacity to alleviate inflammatory pain while limiting immunosuppressive glucocorticoid stress during major surgery, thus harboring therapeutic benefits for oncological procedures. Recently, the molecular mechanisms of DEX-mediated anticancer effects have been partially deciphered. Together with additional preclinical data, these mechanistic insights support the hypothesis that DEX-induced therapeutic benefits are mediated via the stimulation of adaptive anti-tumor immune responses. Similarly, published clinical trials including ancillary studies described an immunostimulatory role of DEX during the perioperative period of cancer surgery. The impact of DEX on long-term patient survival remains elusive. Nevertheless, DEX-mediated immunostimulation offers an interesting therapeutic option for onco-anesthesia. Our present review comprehensively summarizes data from preclinical and clinical studies as well as from ongoing trials with a distinct focus on the role of DEX in overcoming (tumor microenvironment (TME)-imposed) cancer therapy resistance. The objective of this update is to guide clinicians in their choice toward immunostimulatory onco-anesthetic agents that have the capacity to improve disease outcome.https://www.tandfonline.com/doi/10.1080/2162402X.2024.2327143Cancerdexmedetomidineimmunityopioid-free-anesthesia |
| spellingShingle | Killian Carnet Le Provost Oliver Kepp Guido Kroemer Lucillia Bezu Trial watch: dexmedetomidine in cancer therapy OncoImmunology Cancer dexmedetomidine immunity opioid-free-anesthesia |
| title | Trial watch: dexmedetomidine in cancer therapy |
| title_full | Trial watch: dexmedetomidine in cancer therapy |
| title_fullStr | Trial watch: dexmedetomidine in cancer therapy |
| title_full_unstemmed | Trial watch: dexmedetomidine in cancer therapy |
| title_short | Trial watch: dexmedetomidine in cancer therapy |
| title_sort | trial watch dexmedetomidine in cancer therapy |
| topic | Cancer dexmedetomidine immunity opioid-free-anesthesia |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2024.2327143 |
| work_keys_str_mv | AT killiancarnetleprovost trialwatchdexmedetomidineincancertherapy AT oliverkepp trialwatchdexmedetomidineincancertherapy AT guidokroemer trialwatchdexmedetomidineincancertherapy AT lucilliabezu trialwatchdexmedetomidineincancertherapy |